To assist surgeons to select a total hip replacement (THR) we present comparative information on all such implants on the market in the UK.
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0301-620X/95/4992 $2.00 are performed annually in the UK (Williams et al 1992) and the number is increasing (Buistrode and Murray 1992) . It is therefore important that only long-lasting and reliable implants are used.
Many new designs of THR have been introduced in recent years. Most will have been tested in a laboratory, but unlike new drugs, there is at present no formal requirement for clinical tests before a new design is available for sale on the open market. The introduction of the new European CE mark may make clinical trials mandatory (Council Direc tive 93/42/EEC 1993), but the results of such trials may be difficult to interpret. Early overall assessments are usually carried out with clinical scoring systems based on relief of pain and improvement in function and movement . There are, however, a number of different scoring systems in use and these cannot be directly compared (Bryant et al 1993) . Long-term outcome is usually meas ured as time to revision, using survival analysis. This too is liable to distortion which makes comparison of outcome difficult (Murray, Carr and Bulstrode 1993) .
Our aim was to reviewall the designsof THR available in the UK, and to assess how much is known about their clinical performance.
METHOD
In 1994 we identified all manufacturers and distributors of hip implants in the UK and requested specific information about all the primary THR prostheses that they were sell ing. They were asked to provide the date of release on to the market, the estimated market share, the cost, the design features and references for any published clinical results. These and other references related to the implants were critically reviewed and summarised. The information was collated in a table and sent back to the distributor or manufacturer who was asked to check the information and suggest any corrections or additions which were necessary. This checking process was repeated twice.
We have tabulated the implants according to the method of fixation and then according to price, with the cheapest first (Table I) . Other information is shown under the follow ing headings: Year of release UK (other) . This is the year in which the implant was released on to the UK market, followed in parentheses by the year in which it was released on to any other market if this was earlier than that for the UK. 
RESULTS
We identified 19 implant distributors or manufacturers (Table II) . Only one was unwilling to have the THR which it sells presented in this study. The information about the implants sold by this company is freely available and these details have therefore been included. The information may, however, not be completely correct, since it was not con firmed by the manufacturer.
We identified62 differentTHRs (TableI). Many stems and sockets were sold independently, to allow surgeons to use different combinations. We included all such stems, but seven sockets sold independently were excluded. One implant was bipolar.The number of new implants intro duced to the UK marketeach year has increasedsteadily: nine (15%) were introducedin 1993 and seven (11%) in 1992. Only four of those still on the market were intro duced before 1980, and about 50% were added in the last five years. Only the Charnley prosthesis was reported to have a market share of greater than 20%, and eight implants (8%) were said to have a share of between 5% and 20%. The information about market share may not be reliable: manufacturers were unwilling to give this informa tion, but it can be obtained from other sources (Newman 1993) . The prices ranged from Â£250to Â£2000.Most, if not all, manufacturers offer discounts but no useful information was available on this. The prices in other countries are often different from UK prices because of factors such as distribution costs. Some 29 of the THRs (47%) are designed to be cemented (price Â£250to Â£750);nine (15%) can be either cemented or cementless (price Â£355to Â£1250) and 24 (39%) are for cementless use (i@486 to Â£2000).
Advertising for each of the implants claims a unique combination of features which make them better than other previously designed implants. Fourteen (23%) are said to be based on an implant that has previously been shown to be successful. Five femoral stems were monobloc, six were either modular or monobloc, and the remainder were modular.
There are reports of five-year survival results in peer reviewed journals for only eight implants. 
DISCUSSION
The number of THR designs available to surgeons is rapidly increasing, but there are no published results for most of the implants. Some of the new implants will undoubtedly be unsatisfactory and will result in consider able patient suffering and expense. The problem of choice is difficult in the UK, with 62 THRs on the market, but it is worse world-wide. One company, to take an example, markets only three designs of THR in the UK, but world wide it markets 49. There is a need for a thorough review of the factors which are involved in the implant market.
The THR with the longest follow-up is the Charnley design. It is widely considered to be the best standard for comparison (Bulstrode 1987; Wroblewski and Siney 1993) , with a published 20-year survival rate of between 85% and 90% (Schulte et al 1993; Neumann, Freund and SÃ˜renson 1994 a,.. a. 
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Cs 00 00 00 V C'-â€˜0 The results of a THR depend on a number of factors, only one of which is the implant. Other, possibly more important factors, are the techniques used, the instrumenta tion, the skill of the surgeon, experience with that particular implant, and many patient-related factors. It is therefore important that surgeons should make the decision as to which implant should be used for each patient. This deci sion should be based primarily on sound clinical evidence.
The surgeon must be certain (and be able to justify to others) that the implant will provide clinical results at least as good as those for the currently available prostheses known to give the best long-termclinical outcome.Other factorsare of secondaryimportance.Implantsthat perform well in preclinical laboratory testing may not necessarily perform satisfactorily in the clinical situation. Cheap implants are often copies of more established implants, but with minor alterations, theoretically designed to improve theirfunction.if thesealterationsproveto be unsatisfactory in the longer term, the small early saving for the purchaser will result in the large late cost of early revision surgery. It is clear that many, apparently minor alterations, which on theoretical grounds should improve clinical outcome, such as stem shape, surface finish, precoating and metal backing, THE JOURNAL OF BONE AND JOINT SURGERY may in practice make things worse not better (Fowler et al 1988; Wilson-MacDonald and Morscher 1990; Keating 1993; Gardiner and Hozack 1994) .
About 90% of implants are now modular, and although this offers some advantages, it is not without complications (Barrack et al 1993) . The new modular implants will need to be monitored carefully, because clinical results from their monobloc forebears cannot be extrapolated to modular derivative designs.
The relevant information on which to base the choice of THR should be available in an unbiased and readily assim ilable form. Table I is a step towards this, and should be used in conjunction with more detailed information from manufacturers (Table II) and from journals. We have not attempted a mets-analysis because of the lack of available data. Instead we selected representative papers. The refer ences were obtained mainly from the manufacturers as we believe that they should have this information readily available.
Clinical results not published in peer-reviewed journals must be interpreted with extreme caution. For example, one manufacturer's advertising states that â€oethe unaltered stem design has been successfully used in thousands of implanta tions since 1985 with no report of aseptic looseningâ€•,when it is known to the orthopaedic community that there have been such revisions (British Hip Society 1994). We plan to maintain and expand our database and would welcome more information on the clinical results of implants which have been published in peer-reviewed journals anywhere in the world.
There are problems with using clinical results as a basis on which to choose an implant, the most important of which is that there are very few randomised trials which compare implants (Bradley 1994; Marston and Bentley 1994) . Most implants are modified every few years and the results of long-term trials may therefore have little rele vance to the implants currently being used. There is even some evidence to suggest that the Charnley THR which is now available may not be as successful as earlier versions
(Dali etal 1988).
It is probably fair to say that implants with ten-year survival results as good as those for the Charnley design will be approximately as good in the long term. This may apply to some but not all implants with good five-year results: recently, an uncemented THR with a five-year survival similar to that for the Charnley (Malchau et al 1993) was shown to have an eight-year survival which was much worse (Owen et al 1994) . Survival analysis has a number of potential problems , not all of which are circumvented by using large numbers as in the Swedish hip register (Mal chau et al 1993) . Although comparisons between implants are most easily made with survival analysis, it is clear that some implants may be good even if they have not had a long-term survival analysis. For example the Exeter THR has reports of results after up to 16 years' follow-up (Fowler et al 1988) , but no long-term survival study has yet been published. If this was done, it would not necessarily show very good results, because there were early failures for various technical reasons such as a change in surface finish and over-machining, which have now been identified and corrected (Fowler et al 1988; Malchau et al 1993) . It has been suggested that some new implants are performing beuer at five years than the Chamley THR (Malchau et al 1993) . This evidence is weak; other factors, particularly surgeon-dependent ones, may be responsible for the good results (Malchau et al 1993) . The only valid method of comparing implants and identifying other important vari ables, especially those which are surgeon-and technique related is to organise and perform randomised multicentre trials (Bulstrode et al 1993) .
The large number of implants on the market, most of which have no published results, is unsatisfactory and is almost certainly causing harm to patients. The simplest way to address this problem is for orthopaedic surgeons to select implants on the basis of good clinical results published in peer-reviewed journals (Goodfellow 1992 implants with no published clinical data only when they are included in a properly conducted trial or register. The intro duction of the CE mark provides an important opportunity to rationalise the implant market in Europe.
